ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
one-third of one redeemable warrant |
||||
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
☒ | Smaller reporting company | |||||
Emerging growth company |
Page |
||||||
1 |
||||||
4 |
||||||
Item 1. |
4 |
|||||
Item 1A. |
26 |
|||||
Item 1B. |
63 |
|||||
Item 2. |
63 |
|||||
Item 3. |
63 |
|||||
Item 4. |
63 |
|||||
64 |
||||||
Item 5. |
64 |
|||||
Item 6. |
64 |
|||||
Item 7. |
65 |
|||||
Item 7A. |
68 |
|||||
Item 8. |
68 |
|||||
Item 9. |
68 |
|||||
Item 9A. |
69 |
|||||
Item 9B. |
71 |
|||||
Item 9C. |
71 |
|||||
71 |
||||||
Item 10. |
71 |
|||||
Item 11. |
81 |
|||||
Item 12. |
81 |
|||||
Item 13. |
83 |
|||||
Item 14. |
85 |
|||||
Item 15. |
F-1 |
• | our ability to select an appropriate target business or businesses; |
• | our ability to complete our initial business combination; |
• | our expectations around the performance of a prospective target business or businesses; |
• | our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
• | our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; |
• | our potential ability to obtain additional financing to complete our initial business combination; |
• | our pool of prospective target businesses; |
• | our ability to consummate an initial business combination due to the uncertainty resulting from the COVID-19 pandemic; |
• | the ability of our officers and directors to generate a number of potential business combination opportunities; |
• | our public securities’ potential liquidity and trading; |
• | the lack of a market for our securities; |
• | the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
• | the trust account not being subject to claims of third parties; and |
• | or our financial performance following our initial public offering. |
• | We are a recently incorporated company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective. |
• | Past performance by H.I.G. Capital, our management team, our board of directors or their respective affiliates may not be indicative of future performance of an investment in us. |
• | Our shareholders may not be afforded an opportunity to vote on our proposed initial business combination, which means we may complete our initial business combination even though a majority of our shareholders do not support such a combination. |
• | Your only opportunity to affect the investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash. |
• | If we seek shareholder approval of our initial business combination, our sponsor and members of our management team have agreed to vote in favor of such initial business combination, regardless of how our public shareholders vote. |
• | The ability of our public shareholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into a business combination with a target. |
• | The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares may not allow us to complete the most desirable business combination or optimize our capital structure. |
• | The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares could increase the probability that our initial business combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your shares. |
• | We may engage the underwriters or one of their affiliates to provide additional services to us. The underwriters are entitled to receive deferred commissions from our initial public offering that will be released from the trust only on the completion of an initial business combination. These financial incentives may cause the underwriters to have potential conflicts of interest in rendering any such additional services to us. |
• | The requirement that we consummate an initial business combination within 24 months after the closing of our initial public offering may give potential target businesses leverage over us in negotiating a business combination and may limit the time we have in which to conduct due diligence on potential business combination targets, in particular as we approach our dissolution deadline, which could undermine our ability to complete our initial business combination on terms that would produce value for our shareholders. |
• | Changes in the market for directors and officers liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial business combination. |
• | Our search for a business combination, and any target business with which we ultimately consummate a business combination, may be materially adversely affected by the coronavirus (COVID-19) outbreak and the status of debt and equity markets. |
• | We may not be able to consummate an initial business combination within 24 months after the closing of our initial public offering, in which case we would cease all operations except for the purpose of winding up and we would redeem our public shares and liquidate. |
• | If we seek shareholder approval of our initial business combination, our sponsor, directors, executive officers, advisors and their affiliates may elect to purchase public shares or warrants, which may influence a vote on a proposed business combination and reduce the public “float” of our Class A ordinary shares or public warrants. |
• | If a shareholder fails to receive notice of our offer to redeem our public shares in connection with our initial business combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed. |
• | You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced to sell your public shares or warrants, potentially at a loss. |
• | NYSE may delist our securities from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions. |
• | You will not be entitled to protections normally afforded to investors of many other blank check companies. |
• | If we seek shareholder approval of our initial business combination and we do not conduct redemptions pursuant to the tender offer rules, and if you or a “group” of shareholders are deemed to hold in excess of 15% of our Class A ordinary shares, you will lose the ability to redeem all such shares in excess of 15% of our Class A ordinary shares. |
• | Because of our limited resources and the significant competition for business combination opportunities, it may be more difficult for us to complete our initial business combination. |
• | If we have not consummated our initial business combination within the required time period, our public shareholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless. |
• | If the net proceeds of our initial public offering and the sale of the private placement warrants not being held in the trust account are insufficient to allow us to operate for the 24 months following the closing of our initial public offering, it could limit the amount available to fund our search for a target business or businesses and our ability to complete our initial business combination, and we will depend on loans from our sponsor, its affiliates or members of our management team to fund our search and to complete our initial business combination. |
• | The other risks and uncertainties discussed in Item 1A. Risk Factors and elsewhere in this Report. |
• | have a defensible core business with sustainable competitive advantages and differentiated value proposition. |
• | are in attractive, resilient and secularly growing end-markets. |
• | have unrealized strategic and operational upside. |
• | can generate compelling risk-adjusted returns. |
• | can operate successfully under the scrutiny of public markets. |
• | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination; and |
• | cause us to depend on the marketing and sale of a single product or limited number of products or services. |
• | We issue ordinary shares that will be equal to or in excess of 20% of the number of our ordinary shares then-outstanding (other than in a public offering); |
• | Any of our directors, officers or substantial security holder (as defined by the NYSE rules) has a 5% or greater interest, directly or indirectly, in the target business or assets to be acquired or otherwise and the present or potential issuance of ordinary shares could result in an increase in issued and outstanding ordinary shares or voting power of 1% or more (or 5% or more if the related party involved is classified as such solely because such person is a substantial security holder); or |
• | The issuance or potential issuance of ordinary shares will result in our undergoing a change of control. |
• | the timing of the transaction, including in the event we determine shareholder approval would require additional time and there is either not enough time to seek shareholder approval or doing so would place the company at a disadvantage in the transaction or result in other additional burdens on the company; |
• | the expected cost of holding a shareholder vote; |
• | the risk that the shareholders would fail to approve the proposed business combination; |
• | other time and budget constraints of the company; and |
• | additional legal complexities of a proposed business combination that would be time-consuming and burdensome to present to shareholders. |
• | conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules; and |
• | file proxy materials with the SEC. |
• | conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers; and |
• | file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies. |
• | may significantly dilute the equity interest of investors in our initial public offering, which dilution would increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one |
• | may subordinate the rights of holders of Class A ordinary shares if preference shares are issued with rights senior to those afforded our Class A ordinary shares; |
• | could cause a change in control if a substantial number of Class A ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; |
• | may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; |
• | may adversely affect prevailing market prices for our units, Class A ordinary shares and/or warrants; and |
• | will not result in adjustment to the exercise price of our warrants. |
• | default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
• | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
• | our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand; |
• | our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding; |
• | our inability to pay dividends on our Class A ordinary shares; |
• | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A ordinary shares if declared, expenses, capital expenditures, acquisitions and other general corporate purposes; |
• | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
• | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
• | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt. |
• | solely dependent upon the performance of a single business, property or asset; or |
• | dependent upon the development or market acceptance of a single or limited number of products, processes or services. |
• | we have a board that includes a majority of ‘independent directors,’ as defined under the rules of the NYSE; |
• | we have a compensation committee of our board that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and |
• | we have nominating and corporate governance committees of our board that are comprised entirely of independent directors each with a written charter addressing the committee’s purpose and responsibilities. |
• | restrictions on the nature of our investments; and |
• | restrictions on the issuance of securities, |
• | registration as an investment company with the SEC; |
• | adoption of a specific form of corporate structure; and |
• | reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations. |
• | a limited availability of market quotations for our securities; |
• | reduced liquidity for our securities; |
• | a determination that our Class A ordinary shares are a “penny stock” which will require brokers trading in our Class A ordinary shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; |
• | a limited amount of news and analyst coverage; and |
• | a decreased ability to issue additional securities or obtain additional financing in the future. |
• | costs and difficulties inherent in managing cross-border business operations; |
• | rules and regulations regarding currency redemption; |
• | complex corporate withholding taxes on individuals; |
• | laws governing the manner in which future business combinations may be effected; |
• | exchange listing and/or delisting requirements; |
• | tariffs and trade barriers; |
• | regulations related to customs and import/export matters; |
• | local or regional economic policies and market conditions; |
• | unexpected changes in regulatory requirements; |
• | longer payment cycles; |
• | tax issues, such as tax law changes and variations in tax laws as compared to the United States; |
• | currency fluctuations and exchange controls; |
• | rates of inflation; |
• | challenges in collecting accounts receivable; |
• | cultural and language differences; |
• | employment regulations; |
• | underdeveloped or unpredictable legal or regulatory systems; |
• | corruption; |
• | protection of intellectual property; |
• | social unrest, crime, strikes, riots and civil disturbances; |
• | regime changes and political upheaval; |
• | terrorist attacks and wars; and |
• | deterioration of political relations with the United States. |
Name |
Age |
Position | ||
Brian Schwartz |
55 | Chief Executive Officer and Director | ||
Rob Wolfson |
50 | President and Director | ||
Timur Akazhanov |
41 | Chief Financial Officer | ||
Richard Siegel |
57 | Vice President and General Counsel | ||
Andreas Beroutsos |
56 | Director | ||
William E. Mitchell |
78 | Director | ||
Christopher O’Connell |
56 | Director | ||
Sidney Taurel |
74 | Director |
• | meeting with our independent registered public accounting firm regarding, among other issues, audits, and adequacy of our accounting and control systems; |
• | monitoring the independence of the independent registered public accounting firm; |
• | verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; |
• | inquiring and discussing with management our compliance with applicable laws and regulations; |
• | pre-approving all audit services and permitted non-audit services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed; |
• | appointing or replacing the independent registered public accounting firm; |
• | determining the compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; |
• | establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; |
• | monitoring compliance on a quarterly basis with the terms of our initial public offering and, if any noncompliance is identified, immediately taking all action necessary to rectify such noncompliance or otherwise causing compliance with the terms of our initial public offering; and |
• | reviewing and approving all payments made to our existing shareholders, executive officers or directors and their respective affiliates. Any payments made to members of our audit committee will be reviewed and approved by our board of directors, with the interested director or directors abstaining from such review and approval. |
• | should have demonstrated notable or significant achievements in business, education or public service; |
• | should possess the requisite intelligence, education and experience to make a significant contribution to the board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and |
• | should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the shareholders. |
• | reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, evaluating our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation; |
• | reviewing and approving the compensation of all of our other Section 16 executive officers; |
• | reviewing our executive compensation policies and plans; |
• | implementing and administering our incentive compensation equity-based remuneration plans; |
• | assisting management in complying with our proxy statement and annual report disclosure requirements; |
• | approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees; |
• | producing a report on executive compensation to be included in our annual proxy statement; and |
• | reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. |
• | duty to act in good faith in what the director or officer believes to be in the best interests of the company as a whole; |
• | duty to exercise powers for the purposes for which those powers were conferred and not for a collateral purpose; |
• | directors should not improperly fetter the exercise of future discretion; |
• | duty to exercise powers fairly as between different sections of shareholders; |
• | duty not to put themselves in a position in which there is a conflict between their duty to the company and their personal interests; and |
• | duty to exercise independent judgment. |
Individual |
Entity |
Entity’s Business |
Affiliation | |||
Brian Schwartz | H.I.G. Capital, LLC | Asset Management | Co-President | |||
Investment Committees of H.I.G. Capital, LLC funds | Asset Management | Committee Member | ||||
Certain H.I.G. Capital Committees Certain | Asset Management | Committee Member | ||||
Portfolio Companies of H.I.G. Capital, LLC | Asset Management | Board Member | ||||
Rob Wolfson | H.I.G. Capital, LLC | Asset Management | Executive Managing Director; Head of H.I.G. Advantage Fund; Head of U.S. Healthcare | |||
Investment Committees of H.I.G. Capital, LLC funds | Asset Management | Committee Member | ||||
Certain H.I.G. Capital Committees Certain | Asset Management | Committee Member | ||||
Portfolio Companies of H.I.G. Capital, LLC | Asset Management | Board Member | ||||
Certain family real estate LLCs | Real Estate | Member-Manager | ||||
Northwestern University’s School of Education and Social Policy | Education Institution | Advisory Board Member |
Individual |
Entity |
Entity’s Business |
Affiliation | |||
Timur Alkazhanov | H.I.G. Capital, LLC | Asset Management | Managing Director of H.I.G. Technology Partners | |||
Family-Owned LLC | Real Estate | Member Manager | ||||
Richard Siegel | H.I.G. Capital, LLC | Asset Management | General Counsel and Chief Compliance Officer | |||
Certain H.I.G. Capital Committees | Asset Management | Committee Member | ||||
Certain Portfolio Companies of H.I.G. Capital, LLC | Asset Management | Board Member | ||||
Outreach360 | Non-Profit Organization |
Board Member | ||||
Andreas Beroutsos | BW Group | Maritime Transportation and Energy Company | Managing Director | |||
Cadeler A/S | Offshore Wind Turbine Transportation and Installation | Board Member | ||||
Certain BW Group Private Affiliates | Renewable Energy and Organic Fertilizers | Board Member | ||||
Navigator Holdings Ltd. | Gas Transportation | Board Member | ||||
PetSmart, Inc. | Pet Supplies Company | Board Member | ||||
William E. Mitchell | Sequel Venture Partners | Asset Management | Founder & Managing Partner | |||
UCLA Technology Development Group | Education and Technology Non-Profit |
Chairman | ||||
C-Combinator |
Sargassum Harvesting and Product Company | Advisory Board Member | ||||
4L Ultimate Topco Corp. d/b/a Clover Wireless |
Communications Company | Board Member | ||||
Sage Partners | Consulting Firm | Partner | ||||
Christopher O’Connell | Northwestern University’s Weinberg College of Arts and Sciences | Education Institution | Board of Visitors Member | |||
Northwestern University’s Chemistry of Life Processes Institute | Education Institution | Board of Advisors Member | ||||
Ron Burton Training Village | Non-Profit Leadership Academy |
Board Member | ||||
New Mountain Capital | Private Equity Company | Senior Advisor | ||||
Covaris, Inc. | Manufacturer of Life Sciences Technology | Executive Chairman | ||||
Aceto Corporation | Virtual Manufacturer of Chemical Compounds | Director | ||||
Revo Health | Managed-Services Company | Advisory Board Member | ||||
Sidney Taurel | Eli Lilly & Company | Pharmaceutical Company | Chairman Emeritus | |||
Association of Tennis Professionals | Governing Body of Men’s Professional Tennis | Audit and Finance Committee Member |
Individual |
Entity |
Entity’s Business |
Affiliation | |||
Pearson plc | Education and Publishing Company | Chairman | ||||
Columbia Business School | Education Institution | Board of Overseers Member | ||||
Taurel Associates LP | Investment Partnership | Partner | ||||
EuroCapital Investors LLC | Investment Company | Chief Operating Officer | ||||
Kathryn and Sidney Taurel Foundation Inc. | Family Foundation | Officer President | ||||
Taurel Family Management Company | Family Real Estate Company | President | ||||
Taurel Family Holdings, LLLP | Family Real Estate Company | Limited Partner |
• | Our officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our executive officers and directors is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our executive officers and directors are not obligated to contribute any specific number of hours per week to our affairs. |
• | Our sponsor subscribed for founder shares and purchased private placement warrants in a transaction that closed simultaneously with the closing of our initial public offering. |
• | each person known by us to be the beneficial owner of more than 5% of our outstanding ordinary shares; |
• | each of our executive officers and directors that beneficially owns our ordinary share; and |
• | all our executive officers and directors as a group. |
Class B ordinary shares |
Class A ordinary shares |
|||||||||||||||
Name of Beneficial Owners (1) |
Number of Shares Beneficially Owned |
Approximate Percentage of Class |
Number of Shares Beneficially Owned |
Approximate Percentage of Class |
||||||||||||
H.I.G. Acquisition Advisors, LLC (our sponsor) |
8,958,625 | 98.5 | % | — | — | |||||||||||
Directors and Officers |
||||||||||||||||
Brian Schwartz(2) |
8,958,625 | 98.5 | % | — | — | |||||||||||
Rob Wolfson(2) |
8,958,625 | 98.5 | % | — | — | |||||||||||
Timur Akazhanov |
— | — | — | — | ||||||||||||
Richard Siegel |
— | — | — | — | ||||||||||||
Andreas Beroutsos |
35,000 | * | % | — | — | |||||||||||
William E. Mitchell |
35,000 | * | % | — | — | |||||||||||
Christopher O’Connell |
35,000 | * | % | — | — | |||||||||||
Sidney Taurel |
35,000 | * | % | — | — | |||||||||||
All directors and officers as a group (8 individuals) |
9,098,625 | 100 | % | — | — | |||||||||||
Other Beneficial Holders |
||||||||||||||||
Integrated Core Strategies (US) LLC(3) |
— | — | 2,123,145 | 5.8 | % | |||||||||||
Linden Capital L.P.(4) |
— | — | 2,427,842 | 6.7 | % | |||||||||||
Arena Capital Advisors, LLC—CA(5) |
— | — | 2,295,280 | 5.5 | % | |||||||||||
Glazer Capital, LLC(6) |
— | — | 3,006,419 | 8.3 | % |
* | Less than one percent. |
(1) |
Unless otherwise noted, the business address of each of our shareholders is 1450 Brickell Avenue, 31st Floor, Miami, FL 33131. |
(2) |
The shares reported above are held in the name of our sponsor. Our sponsor is controlled by a board of managers that consists of Messrs. Schwartz and Wolfson. |
(3) |
Includes Class A ordinary shares beneficially held by Integrated Core Strategies (US) LLC, a Delaware limited liability company (“ICS”), Riverview Group LLC, a Delaware limited liability company (“RG”), ICS Opportunities, Ltd., a Cayman Islands exempted company (“ICSO”), ICS Opportunities II LLC, a Cayman Islands limited liability company (“ICSO II”), Integrated Assets, Ltd., a Cayman Islands exempted company (“IA”), Millennium International Management LP, a Delaware limited partnership (“MIM”), Millennium Management LLC, a Delaware limited liability company (“MI”), Millennium Group Management LLC, a Delaware limited liability company (“MGM”), and Israel Englander, the managing member of Millennium Group Management and a United States citizen (“Mr. Englander”), based solely on the Schedule 13G/A filed jointly by ICS, RG, ICSO, ICSO II, IA, MIM, MI, MGM, and Mr. Englander, with the SEC on February 1, 2022. The business address of each of ICS, RG, ICSO II, IA, MIM, MI, MGM, and Mr. Englander is Millennium Management LLC, 399 Park Avenue, New York, New York 10022. |
(4) |
Includes Class A ordinary shares beneficially held by Linden Capital L.P., a Bermuda limited partnership (“LCLP”), Linden GP LLC, a Delaware limited liability company (“LGP”), Linden Advisors LP, a Delaware limited partnership (“LALP”), and Siu Min Wong, the principal owner and controlling person of LALP and LGP and a Chinese and United States Citizen (“Mr. Wong”), based solely on the Schedule 13G/A filed by LCLP, LGP, LALP, and Mr. Wong on January 31, 2022. The principal business address for LCLP is Victoria Place, 31 Victoria Street, Hamilton HM10, Bermuda. The principal business address for each of LALP, LGP, and Mr. Wong is 590 Madison Avenue, 15th Floor, New York, New York 10022. |
(5) |
Includes Class A ordinary shares beneficially held by Arena Capital Advisors, LLC—CA, a Delaware limited liability corporation (“ACA”), Arena Short Duration High Yield Fund, LP—Series A, a Delaware limited partnership (“AF-A”), Arena Short Duration High Yield Fund, LP—Series B, a Delaware limited partnership (“AF-B”), Arena Short Duration High Yield Fund, LP—Series C, a Delaware limited partnership (“AF-C”), Arena Short Duration High Yield Fund, LP—Series E, a Delaware limited partnership (“AF-E”), Arena Capital Fund, LP—Series 8, a Delaware limited partnership (“ACF-8), and Arena Capital Fund, LP—Series 16, a Delaware limited partnership (“ACF-16”), based solely on the Schedule 13G/A filed by ACA, AF-A, AF-B, AF-C, AF-E, ACF-8, and ACF-16 on February 11, 2022. The principal business address for CA, AF-A, AF-B, AF-C, AF-E, ACF-8, and AF-16 is 12121 Wilshire Blvd., Ste. 1010, Los Angeles, CA 90025. |
(6) |
Includes Class A ordinary shares beneficially held by Glazer Capital, LLC, a Delaware limited liability company (“GC”) with respect to Class A ordinary shares held by certain funds and managed accounts to which GC serves as investment manager (collectively, the “Glazer Funds”), and Paul J. Glazer, the Managing Member of GC with respect to the Class A ordinary shares held by the Glazer Funds and a United States Citizen (“Mr. Glazer”), based solely on the Schedule 13G filed by GC and Mr. Glazer on February 14, 2022. The principal business address for GC and Mr. Glazer is 250 West 55th Street, Suite 30A, New York, New York 10019. |
* | Filed herewith |
** | Furnished herewith |
(1) | Incorporated by reference to the registrant’s Registration Statement on Form S-1, filed with the SEC on September 28, 2020 |
(2) | Incorporated by reference to the registrant’s Current Report on Form 8-K, filed with the SEC on October 26, 2020. |
(3) | Incorporated by reference to the registrant’s Annual Report on Form 10-K, filed with the SEC on March 30, 2021. |
H.I.G. ACQUISITION CORP. | ||||||
/s/ Brian D. Schwartz | ||||||
March 29, 2022 | Name: | Brian D. Schwartz | ||||
Title: | Chief Executive Officer | |||||
(Principal Executive Officer) |
/s/ Brian D. Schwartz |
Chief Executive Officer and Director | March 29, 2022 | ||
Brian D. Schwartz | (Principal Executive Officer) | |||
/s/ Timur Akazhanov |
Chief Financial Officer | March 29, 2022 | ||
Timur Akazhanov | (Principal Financial Officer and Principal Accounting Officer) | |||
/s/ Rob Wolfson |
President and Director | March 29, 2022 | ||
Rob Wolfson | ||||
/s/ William E. Mitchell |
Director | March 29, 2022 | ||
William E. Mitchell | ||||
/s/ Andreas Beroutsos |
Director | March 29, 2022 | ||
Andreas Beroutsos | ||||
/s/ Christopher O’Connell |
Director | March 29, 2022 | ||
Christopher O’Connell | ||||
/s/ Sidney Taurel |
Director | March 29, 2022 | ||
Sidney Taurel |
F-2 |
||||
Financial Statements: |
||||
F-3 |
||||
F-4 |
||||
F-5 |
||||
F-6 |
||||
F-7 |
December 31, |
December 31, |
|||||||
2021 |
2020 |
|||||||
ASSETS |
||||||||
Cash |
$ | $ | ||||||
Prepaid expenses |
||||||||
Total current assets |
||||||||
Investments held in Trust Account |
||||||||
Total Assets |
$ |
$ |
||||||
LIABILITIES , CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses |
||||||||
Due to related party |
||||||||
Total current liabilities |
||||||||
Deferred underwriting commissions |
||||||||
Derivative warrant liabilities |
||||||||
Total liabilities |
||||||||
Commitments and Contingencies (Note 5) |
||||||||
Class A ordinary shares subject to possible redemption, |
||||||||
Shareholders’ deficit |
||||||||
Preference shares, $ |
||||||||
Class A ordinary shares, $ |
||||||||
Class B ordinary shares, $ |
||||||||
Additional paid-in capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
Total shareholders’ deficit |
( |
) | ( |
) | ||||
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit |
$ |
$ |
||||||
For The Period From |
||||||||
September 2, 2020 |
||||||||
For The Year Ended |
(Inception) Through |
|||||||
December 31, 2021 |
December 31, 2020 |
|||||||
Formation and operating costs |
$ | $ | ||||||
|
|
|
|
|||||
Loss from operations |
( |
) | ( |
) | ||||
Change in fair value of derivative warrant liabilities |
( |
) | ||||||
Financing costs - derivative warrant liabilities |
( |
) | ||||||
Net gain from investments held in Trust Account |
||||||||
|
|
|
|
|||||
Net income (loss) |
$ | $ | ( |
) | ||||
|
|
|
|
|||||
Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted |
||||||||
|
|
|
|
|||||
Basic and diluted net income (loss) per share, Class A ordinary s subject to possible redemptionhares |
$ |
$ |
( |
) | ||||
|
|
|
|
|||||
Weighted average shares outstanding of Class B non-redeemable ordinary shares, basic and diluted |
||||||||
|
|
|
|
|||||
Basic and diluted net income (loss) per share, Class B non-redeemable ordinary shares |
$ |
$ |
( |
) | ||||
|
|
|
|
Ordinary Shares |
Additional |
Total |
||||||||||||||||||
Class B |
Paid-In |
Accumulated |
Shareholders’ |
|||||||||||||||||
Shares |
Amount |
Capital |
Deficit |
Deficit |
||||||||||||||||
Balance as of January 1, 2021 |
$ |
$ |
$ |
( |
) |
$ |
( |
) | ||||||||||||
Net incom e |
— | — | — | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance as of December 31, 2021 |
$ |
$ |
— |
$ |
( |
) |
$ |
( |
) | |||||||||||
|
|
|
|
|
|
|
|
|
|
Ordinary Shares |
Additional |
Total |
||||||||||||||||||
Class B |
Paid-In |
Accumulated |
Shareholders’ |
|||||||||||||||||
Shares |
Amount |
Capital |
Deficit |
Deficit |
||||||||||||||||
Balance as of September 2, 2020 |
$ |
$ |
$ |
$ |
||||||||||||||||
Issuance of ordinary shares to Sponso r |
— | |||||||||||||||||||
Accretion of Class A ordinary shares to redemption value |
— | — | ( |
) | ( |
) | ( |
) | ||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance as of December 31, 2020 |
$ |
$ |
— |
$ |
( |
) |
$ |
( |
) | |||||||||||
|
|
|
|
|
|
|
|
|
|
For The Year Ended December 31, 2021 |
For The Period From September 2, 2020 (Inception) Through December 31, 2020 |
|||||||
Cash Flows from Operating Activities |
||||||||
Net Income (Loss) |
$ | $ | ( |
) | ||||
Adjustments to reconcile net income (loss) to net cash used in operating activities: |
||||||||
General and administrative expenses paid by Sponsor in exchange for issuance of Class B ordinary shares |
||||||||
Net gain from investments held in Trust Account |
( |
) | ( |
) | ||||
Change in fair value of derivative warrant liabilities |
( |
) | ||||||
Financing costs allocated to derivative warrant liabilities |
||||||||
Changes in operating assets and liabilities: |
||||||||
Prepaid expenses |
( |
) | ||||||
Accounts payable |
||||||||
Accrued expenses |
||||||||
|
|
|
|
|||||
Net cash used by operating activities |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Cash Flows from Investing Activities |
||||||||
Cash deposited in Trust Account |
( |
) | ||||||
|
|
|
|
|||||
Net cash provided by investing activities |
( |
) | ||||||
|
|
|
|
|||||
Cash Flows from Financing Activities |
||||||||
Advances from related party |
|
|
|
|
|
|
|
|
Repayment of note payable to related party |
( |
) | ||||||
Proceeds received from initial public offering, gross |
||||||||
Proceeds received from private placement |
||||||||
Offering costs paid |
( |
) | ||||||
|
|
|
|
|||||
Net cash provided by financing activities |
||||||||
|
|
|
|
|||||
Net increase (decrease) in cash |
( |
) | ||||||
Cash - beginning of period |
||||||||
|
|
|
|
|||||
Cash - end of period |
$ | $ | ||||||
|
|
|
|
|||||
Supplemental disclosure of noncash investing and financing activities: |
||||||||
Offering costs included in accrued expenses |
$ | $ | ||||||
|
|
|
|
|||||
Deferred offering costs paid through promissory note - related party |
$ | $ | ||||||
|
|
|
|
|||||
Deferred underwriting fees payable |
$ | $ | ||||||
|
|
|
|
• | Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
• | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
• | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
Gross proceeds |
$ | |||
Less: |
||||
Deferred underwriting fees and other offering costs |
( |
) | ||
Proceeds allocated to public warrants |
( |
) | ||
Plus: |
||||
Total accretion of carrying value to redemption value |
||||
Class A ordinary shares subject to possible redemption |
$ |
|||
For The Year Ended December 31, 2021 |
For The Period From September 2, 2020 (Inception) Through December 31, 2020 |
|||||||
Redeemable Class A Ordinary Shares |
||||||||
Numerator: Net income (loss) allocable to Redeemable Class A Ordinary Shares |
$ | $ | ( |
) | ||||
Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares |
||||||||
Basic and diluted net income (loss) per share, Redeemable Class A Ordinary Shares |
$ |
$ |
( |
) | ||||
Non-Redeemable Class B Ordinary Shares |
||||||||
Numerator: Net income (loss) allocable to non-redeemable Class B Ordinary Shares |
$ | $ | ( |
) | ||||
Denominator: Weighted Average Non-Redeemable Class B Ordinary Shares |
||||||||
Basic and diluted net income (loss) per share, Non-Redeemable Class B Ordinary Share s |
$ |
$ |
( |
) | ||||
• | in whole and not in part; |
• | at a price of $ |
• | upon a minimum of 30 days’ prior written notice of redemption; and |
• | if, and only if, the last reported sale price (the “closing price”) of the Class A ordinary shares equals or exceeds $ 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
• | in whole and not in part; |
• | at $ |
• | if, and only if, the closing price of the Company’s Class A ordinary shares equals or exceeds $ 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and |
• | the closing price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $ |
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
Assets |
||||||||||||||||
Marketable securities held in Trust Account |
$ | $ | — | $ | — | $ | ||||||||||
Liabilities: |
||||||||||||||||
Public Warrants |
$ | $ | — | $ | — | $ | ||||||||||
Private Placement Warrants |
— | — | ||||||||||||||
Total liabilities |
$ | $ | $ | — | $ | |||||||||||
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
Assets |
||||||||||||||||
Marketable securities held in Trust Account |
$ | $ | — | $ | — | $ | ||||||||||
Liabilities: |
||||||||||||||||
Public Warrants |
$ | $ | — | $ | — | $ | ||||||||||
Private Placement Warrants |
— | — | ||||||||||||||
Total liabilities |
$ | $ | $ | — | $ | |||||||||||